Latest Pharmacy News

ECS Botanics is set to launch AVANI AVA, a new medicinal cannabis range specifically designed for women’s health, aiming to capture a growing market segment with targeted formulations.

Avecho Biotechnology has received patent allowances in the US and Europe for its proprietary CBD soft-gel formulation, reinforcing its intellectual property ahead of pivotal Phase III insomnia trial results expected in mid-2026.

McPherson’s Limited has secured a new $16.2 million debt facility with HSBC, significantly downsizing from its previous $52.5 million arrangement as part of its ongoing business transformation.

ECS Botanics has achieved a milestone with direct-to-consumer sales exceeding 60% of total revenue, driven by the launch of innovative sugar-free THC gummies and a strategic distribution partnership.

AFT Pharmaceuticals delivered a robust first half for FY26, posting 33% revenue growth and a return to profitability, driven by strong Australian sales and recovery in Asia and international markets. The company is advancing its global footprint and R&D pipeline, positioning for sustained growth.

ParagonCare reported solid FY25 results, progressing well on its complex merger integration and expanding its footprint in Asia through the acquisition of Somnotec Group.

Epsilon Healthcare has posted its highest-ever quarterly receipts of $2.919 million, reflecting a robust turnaround since exiting voluntary administration in mid-2024. The company’s strategic sale and leaseback deal has also enabled significant debt reduction, setting the stage for sustained growth.

Epsilon Healthcare reports a strong rebound with a 73% revenue increase in the June quarter, driven by contract manufacturing and new pharmacy operations. The company is emerging from restructuring with renewed financial strength and growth prospects.

Epsilon Healthcare has commenced operations of its new pharmacy division and extended a key loan facility, signaling a strategic pivot towards integrated healthcare and financial stability after recent restructuring.

MedAdvisor Limited has appointed John Ciccio as its new CEO and Managing Director, marking a strategic leadership shift aimed at capitalising on recent technology advancements and US market growth.

Bioxyne Limited, through its subsidiary Breathe Life Sciences, has inked an exclusive deal to import, manufacture, and distribute Curaleaf’s Que Medical Inhalation Device in Australia, with a nationwide launch set for November 2025.

Avecho Biotechnology advances its pivotal Phase III CBD insomnia trial with 160 patients dosed and secures $2.5 million to accelerate manufacturing and regulatory efforts ahead of a 2026 interim analysis.